Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Companies Join to Create Next Gen Upcyte Cells

April 10, 2013 12:42 pm | Drug Discovery & Development | Product Releases | Comments

Medicyte has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next generation, cell-based upcyte cell products to the biopharma and academic research markets.


Chemistry Workbench Get Major Update

April 10, 2013 12:36 pm | Product Releases | Comments

Cresset announced the release of a new version of its computational chemistry workbench forgeV10. This release is the first major update following the launch of forgeV10 in 2012.


Mass Flow Controllers Designed for Industrial Applications

April 10, 2013 12:25 pm | Product Releases | Comments

MKS Instruments Inc. announced the introduction of the I-Series of mass flow controllers designed for use in harsh environments where resistance to liquid or dust ingress (IP66 rated) is essential.


Lilly Debuts New Oncology Data

April 10, 2013 11:32 am | News | Comments

Eli Lilly and Company unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. this week.  The data reflect Lilly's diverse oncology pipeline via molecules that target several pathways...


Resistant Melanoma Responds to Intermittent Treatment

April 10, 2013 9:59 am | News | Comments

Vemurafenib-resistant tumors in patients with melanoma showed reduced growth after cessation of treatment, and in animal models, drug resistance was prevented by intermittent treatment, according to data presented at the AACR Annual Meeting 2013.


Delcath Cuts Staff by 21%

April 9, 2013 3:24 pm | News | Comments

Shares of Delcath Systems Inc. slid further Tuesday after the medical device company said it will eliminate jobs and move its headquarters to reduce its spending. THE SPARK: After the market closed on Monday, Delcath said it will cut costs by eliminating 21 percent of its staff positions...


Genomic Carcinoma Alterations May Lead to New Therapies

April 9, 2013 2:48 pm | News | Comments

Not all head and neck squamous cell carcinomas (HNSCCs) have the same pattern of genomic alterations, but those cancers with certain distinctive patterns could be amenable to specific targeted therapies, according to new research.


Synergy Rises on Plecantide Prospects

April 9, 2013 2:29 pm | News | Comments

Synergy Pharmaceuticals struck a new high for the year, with Cantor Fitzgerald saying it expects greater sales of the company's experimental bowel drug. Analyst Irina Rivkind said she now thinks sales of the drug plecantide could rise to almost $1.6 billion a decade from now.


Centrifan PE Evaporates Without Bumping

April 9, 2013 12:38 pm | Product Releases | Comments

The new Centrifan PE Evaporator/Concentrator from KD Scientific is a small volume evaporator that eliminates the problem of bumping using patented SBT (Self blowdown technology). SBT allows solvent drying using heated, circulating gas flow and no vacuum pump.


PolyScience Baths Have Various Sizes, Capabilities

April 9, 2013 12:28 pm | Drug Discovery & Development | Product Releases | Comments

Available in 40 different models, the PolyScience line of refrigerating/heating circulating baths features temperature ranges as broad as -40 degrees to +200 degrees C, temperature stabilities as exacting as ±0.005 degrees C, and reservoir sizes ranging from 7 to 75 liters.


eTMF System Ensures Inspection Readiness

April 9, 2013 12:17 pm | Product Releases | Comments

PharmaVigilant announced the release of I-Vault 2.7, a robust eTMF system. The system has been expanded to include the new I-Batch uploader, imbedded Redactor tool and the Report Generator.


Gilead Submits NDA for Sofosbuvir

April 9, 2013 12:00 pm | News | Comments

Gilead Sciences announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus (HCV) infection.


Morning Sickness Pill Returns to US

April 9, 2013 11:47 am | News | Comments

Talk about a comeback: A treatment pulled off the market 30 years ago has won Food and Drug Administration approval again as the only drug specifically designated to treat morning sickness. That long-ago safety scare, prompted by hundreds of lawsuits claiming birth defects, proved to be a false alarm.


AstraZeneca Given 'Negative' Rating

April 8, 2013 5:10 pm | News | Comments

Standard & Poor's Ratings Service lowered its credit rating outlook on AstraZeneca PLC on Monday, citing the pharmaceutical company's declining revenue as its patents on Seroquel IR and other key drugs expire. Analyst Olaf Toelke lowered his outlook to "negative" from "stable."


Bristol-Myers Replaces Research Director

April 8, 2013 1:29 pm | by Linda A. Johnson | News | Comments

Bristol-Myers Squibb Co. will replace its top researcher with a physician and former medical school professor who has worked in pharmaceutical industry research for more than two decades. Dr. Francis Cuss, 58, will become the New York-based drugmaker's executive vice president and chief scientific officer on July 1.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.